Antitumor activity of a new antibiotic, kazusamycin.

Abstract
The antitumor activity of a new antibiotic, kazusamycin, against various murine tumors was studied by various treatment schedules. Single, intermittent and successive injections of the antibiotic were almost equally effective against Ehrlich carcinoma, IMC carcinoma and sarcoma 180 tumor, but successive injections showed more efficacy than the other schedules against Meth A fibrosarcoma and Lews lung carcinoma. There was no clear dose response for the efficacy of kazusamycin on murine tumos. When HeLa cells were exposed to kazusamycin for 72 h in vitro, the IC50 value was .apprx. 1 ng/ml and the cytotoxicity of the antibiotic depended on the incubation time.

This publication has 2 references indexed in Scilit: